Protara Therapeutics (TARA) highlighted recent updates and anticipated 2026 milestones. Milestones include: On track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 2026; Received Breakthrough Therapy and Fast Track designations for TARA-002 in LMs; regulatory update expected in 1H 2026; Dosed first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on long-term parenteral support and expect to report interim results in 2H 2026; Recently completed approximately $86 million public offering extending cash runway into 2028
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARA:
- 3 Best Biotech Stocks to Buy Today, 1/7/2026, According to Top Analysts
- Protara doses first patient in Phase 3 trial of IV Choline Chloride
- Protara Therapeutics initiated with an Overweight at Piper Sandler
- Regulatory De-Risking and Expanding Indications Drive Attractive Risk–Reward for Protara Therapeutics’ TARA-002
- Protara gets FDA Breakthrough Therapy and Fast Track Designations for TARA-002